Skip to Content
Merck
CN
  • Early anticoagulation therapy for severe burns complicated by inhalation injury in a rabbit model.

Early anticoagulation therapy for severe burns complicated by inhalation injury in a rabbit model.

Molecular medicine reports (2017-09-26)
Zhong-Hua Fu, Guang-Hua Guo, Zhen-Fang Xiong, Xincheng Liao, Ming-Zhuo Liu, Jinhua Luo
ABSTRACT

The aim of the present study was to determine the effects of early anticoagulation treatment on severe burns complicated by inhalation injury in a rabbit model. Under anesthetization, an electrical burns instrument (100˚C) was used to scald the backs of rabbits for 15 sec, which established a 30% III severe burns model. Treatment of the rabbits with early anticoagulation effectively improved the severe burns complicated by inhalation injury‑induced lung injury, reduced PaO2, PaCO2 and SPO2 levels, suppressed the expression of tumor necrosis factor‑α, interleukin (IL)‑1β and IL‑6, and increased the activity of IL‑10. In addition, it was found that early anticoagulation treatment effectively suppressed the activities of caspase‑3 and caspase‑9, upregulated the protein expression of vascular endothelial growth factor (VEGF) and decreased the protein expression of protease‑activated receptor 1 (PAR1) in the severe burns model. It was concluded that early anticoagulation treatment affected the severe burns complicated by inhalation injury in a rabbit model through the upregulation of VEGF and downregulation of PAR1 signaling pathways. Thus, early anticoagulation is a potential therapeutic option for severe burns complicated by inhalation injury.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-PAR1 antibody produced in mouse, clone 6A7H10, ascites fluid